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In Brief
Parikh et al. show that major
histocompatibility complex class I (MHC-
I)-restricted control of viral infection is
due to natural killer (NK) cells rather than
cytotoxic T cells. Inhibitory NK cell
receptors are essential for protection,
requiring NK cell licensing (education) by
self-MHC-I and missing-self recognition
due to virus-induced MHC-I
downregulation.
NK cells eliminate MCMV-infected 
cells with low H2-Dd expression.
MCMV that does not downregulate H2-Dd is not recognized
by NK cells, but is eliminated by CD8+ T cells.
NK cells lacking Ly49A and Ly49G 
cannot eliminate MCMV-infected cells. 
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SUMMARY
Major histocompatibility complex class I (MHC-I)-restricted immune responses are largely attributed to cyto-
toxic T lymphocytes (CTLs). However, natural killer (NK) cells, as predicted by the missing-self hypothesis,
have opposing requirements forMHC-I, suggesting that theymay also demonstrateMHC-I-restricted effects.
In mice, the Ly49 inhibitory receptors prevent NK cell killing of missing-self targets in effector responses, and
they have a proposed second function in licensing or educating NK cells via self-MHC-I in vivo. Here we show
MHC-I-restricted control of murine cytomegalovirus (MCMV) infection in vivo that is NK cell dependent. Using
mice lacking specific Ly49 receptors, we show that control of MCMV requires inhibitory Ly49 receptors and
an inhibitory signaling motif and the capacity for MCMV to downregulate MHC-I. Taken together, these data
provide definitive evidence that the inhibitory receptors are required for missing-self rejection and are rele-
vant to MHC-I-restricted NK cell control of a viral infection in vivo.
INTRODUCTION
Major histocompatibility complex (MHC) class I (MHC-I) mole-
cules are central to adaptive and innate immune responses.
They are required for adaptive CD8+ MHC-I-restricted T cell
recognition in antigen priming and responses as well as shaping
adaptive T cell receptor repertoires in thymocyte development.
In support of this central role for MHC-I in T cell immunity,
many viruses have evolved mechanisms to suppress MHC-I
expression to thwart T cell effector responses. In innate immu-
nity, MHC-I has opposing effects on natural killer (NK) cells.
The missing-self hypothesis predicts that NK cells should kill
cells that downregulate MHC-I (Ljunggren and Kärre, 1990), as
supported by MHC-I-specific inhibitory NK cell receptors that
prevent NK cell killing of cells with normal MHC-I expression
in vitro (Karlhofer et al., 1992; Kärre et al., 1986). Although sup-
ported by NK cell elimination of adoptively transferred MHC-I-
deficient cells, the role of inhibitory NK cell receptors during
in vivo responses is still poorly understood, largely because of
the large number of polymorphic, germline-encoded receptors
with overlapping specificities and apparently opposing func-
tional outcomes. Improved clarity of these processes is required
to better understand the basis for association of human MHC-I
(HLA-I) alleles with certain diseases, which is generally thought
to be due to CD8+ T cells (Trowsdale and Knight, 2013).
In mice, the Ly49 NK cell receptor family is encoded in a gene
cluster in the NK gene complex (NKC) on mouse chromosome 6
(Yokoyama and Plougastel, 2003). Although Ly49s display pro-
found allelic polymorphisms with several haplotypes and allelic
forms (Rahim and Makrigiannis, 2015), most Ly49s mediate
inhibitory function in effector responses through their cyto-
plasmic immunoreceptor tyrosine-based inhibitory motifs
(ITIMs) (Long et al., 2013). Inhibitory Ly49 receptors bind MHC-
I alleles, but their specificities have been reportedly identical;
for example, Ly49AB6, Ly49CB6, Ly49GB6, and Ly49IB6 all recog-
nize H2Dd (Dam et al., 2003; Hanke et al., 1999). Ly49s are sto-
chastically expressed on overlapping subsets of NK cells with in-
dividual NK cells simultaneously expressing two or more Ly49s,
limiting the capacity to interpret the effects of antibody depletion
studies to a particular receptor specificity or quantitative effects
on NK cell numbers.
The Ly49 receptors also display polymorphism at another
level. In contrast to inhibitory Ly49s, Ly49 activation receptors
lack ITIMs and are coupled to immunoreceptor tyrosine-based
activation motif (ITAM)-containing chains, such as DAP12
(Long et al., 2013), even though theymay be serologically related
to the inhibitory receptors. The Ly49HB6 activation receptor is
responsible for genetic resistance of C57BL/6 (B6) mice to mu-
rine cytomegalovirus (MCMV) infection, providing vital early viral
control, even in mice with intact adaptive immunity (Brown et al.,
2001). Ly49HB6 recognizes an MCMV-encoded MHC-I-like
molecule, m157 (Arase et al., 2002). The Ly49P1NOD/Ltj, Ly49L-
BALB, and Ly49D2PWK/Pas activation receptors serve similar func-
tions, albeit with ligands distinct from m157 (Pyzik et al., 2011).
Additionally, the inhibitory Ly49I129 receptor also binds m157
(Arase et al., 2002; Corbett et al., 2011), suggesting that inhibi-
tory Ly49 receptors could play critical roles in viral control,
through effects that are not well understood.
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Interestingly, the inhibitory Ly49 receptors appear to provide a
second function in a process termed licensing (or education) by
self-MHC-I. Only inhibitory receptors specific for self-MHC-I
in vivo can confer a licensed phenotype whereby licensed NK
cells exhibit enhanced responsiveness to stimulation through
activation receptors in vitro (Kim et al., 2005). Prior studies sug-
gested that licensed NK cells hamper MCMV control through
inhibitory receptors for host MHC-I (Orr et al., 2010). However,
other studies suggest that inhibitory Ly49s may enhance
MCMV control, but these approaches have used mouse strains
with poorly characterized Ly49s and Ly49-depleting antibodies
with unclear specificities and that also affect total NK cell num-
ber, confounding interpretations (Babic et al., 2010; Pyzik
et al., 2011; Pyzik et al., 2014). Additionally, because of the po-
tential roles of other receptors (Guillamón et al., 2018; Rahim
et al., 2015) in licensing, the in vivo role of licensed NK cells
and inhibitory Ly49s in viral infections remains controversial.
Herein, we found that NK cells mediate MHC-restricted con-
trol of MCMV infection. We used CRISPR-Cas9 to simulta-
neously and cleanly target multiple Ly49 receptors, allowing
definitive evaluation of the role of inhibitory Ly49s in MHC-
restricted resistance to MCMV infection.
RESULTS
MHC-Restricted, NK Cell-Dependent Protection against
MCMV in Mice
To investigate the role of NK cells in MCMV control in different
MHC backgrounds, we used C57BL/10 (B10, H2b) and B10.D2
(H2d) MHC-congenic mouse strains that are closely related to
B6 (H2b) and share Ly49 haplotypes (Higuchi et al., 2010). Sus-
ceptibility at day 4 post-infection (d4 p.i.) to wild-type (WT)
MCMV in B10 mice was NK cell dependent, and antibody block-
ing studies showed that protection against WT MCMV was
dependent upon Ly49H (Figure 1A), as shown for B6 mice
(Brown et al., 2001). To examine other mechanisms of viral resis-
tance applicable to MCMV isolates from the wild lacking m157
(Corbett et al., 2011), we used Dm157-MCMV that contains a
Figure 1. H2d-Dependent Protection against MCMV Lacking m157 Requires Cytotoxic NK Cells
(A–F) Splenic viral titers in mice depleted of total NK cells or CD8+ T cells or where Ly49H+ receptors on NK cells were blocked. Data represent a composite of two
independent experiments with three to seven mice per group, with individual points representing a single mouse using (A) H2b-expressing B10 mice, (B) B10 and
H2d-expressing B10.D2 mice, (C) H2Dd-expressing (D8-KODO) mice, and (D–F) D8-KODO mice with wild-type, heterozygous, or no expression of (D) perforin
(Prf1), (E) granzyme B (Gzmb), and (F) NKG2D (Klrk1).
2 Cell Reports 32, 107969, July 28, 2020
Report
ll
OPEN ACCESS
single nucleotide deletion in m157 that prevents full-length
expression. Although B10 mice were unable to control Dm157-
MCMV infection at d4 p.i., MHC-congenic B10.D2 (H2d) mice
were resistant (Figure 1B), demonstrating an MHC-restricted
effect.
To isolate the MHC-restricted effect to a single MHC-I allele,
we showed that Dm157-MCMV resistance was comparable
with B10.D2 mice in B6 mice transgenically expressing only
H2Dd, in the genetic absence of H2Kb andH2Db (D8-KODO) (Fig-
ure 1C), indicating that resistance was specifically due to H2Dd.
Resistance was clearly dependent upon NK cells but not CD8+
T cells, as shown by antibody depletion of NK or CD8+ T cells,
respectively (Figures 1B and 1C). Thus, MHC-restricted resis-
tance toDm157-MCMV is due to H2Dd and is NK cell dependent.
Perforin-deficient (Prf1/) D8-KODO mice were as suscepti-
ble as WT B6 mice, whereas both perforin WT (Prf1+/+) and per-
forin heterozygous (Prf1+/) D8-KODO mice controlled Dm157-
MCMV (Figure 1D). Likewise, granzyme-deficient D8-KODO
mice could not control Dm157-MCMV (Figure 1E). Although
NKG2D enhances NK cell responses to MCMV in B6 mice (Na-
bekura et al., 2017; Zafirova et al., 2009), we found no change
in viral control by NKG2D-deficient D8-KODO mice compared
with D8-KODO mice (Figure 1F). Thus, NK cell-dependent con-
trol ofDm157-MCMV requires cytotoxicity, implying direct target
contact, but NKG2D was not required.
NK Cell Resistance Requires Ly49 Receptor Expression
As Ly49s recognize MHC-I, we assessed their candidacy for be-
ing responsible for the MHC-I-restricted, NK-dependent resis-
tance to Dm157-MCMV by using CRISPR-Cas9 to target their
deletion directly in B6 zygotes. When we used a guide RNA
(gRNA) intentionally chosen for its promiscuity for several
Ly49s, we generated DLy49-1 mice with two distinct deletions:
(1) a 149 kb deletion between Ly49a and Ly49g with an out-of-
frame fusion and (2) a 66 kb deletion between two pseudogenes,
Ly49n (Klra14-ps) and Ly49k (Klra11-ps), such that Ly49h was
deleted (Figure 2A). Flow cytometry confirmed the loss of
Ly49A, Ly49C, Ly49G, and Ly49H expression. Ly49D expression
was markedly decreased, but its coding sequence was intact,
suggesting an as yet unidentified locus control region within
one of the deleted segments.We also generated single and com-
pound Ly49-deleted mice, detailed below (Figures S1 and S2).
Figure 2. NK Cell Resistance to Dm157-MCMV Requires Specific Ly49 Receptors
(A) The CRISPR single-guide RNA (sgRNA) used for targeting is shown; PAM site underlined, 10 nt core in yellow. Mismatches between the sgRNA and targeted
Ly49s are represented below the guide. B6 Ly49 cluster with the number of predicted mismatches is shown below. Loss of genetic regions is indicated as a red
dashed line; flow cytometry histograms indicate wild-type D8-KODO (shaded) and DLy49-1 D8-KODO (solid line) NK cell expression.
(B–E) Dm157-MCMV splenic titers; data represent a composite of at least two independent experiments with three to seven mice per group: (B) D8-KODO,
DLy49-1 D8-KODO and the indicated F1 mice; (C–E) D8-KODO mice (C) lacking DAP10 and DAP12, (D) with Ly49m deletions, and (E) lacking Ly49C and Ly49I.
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Predicted potential off-target sites were absent by PCR amplifi-
cation and sequencing (Table S1). To further eliminate any off-
target effects and genetic mosaicism, we backcrossed all
CRISPR-Cas9 founder mice to WT B6 for two generations, fol-
lowed by additional crosses to KODO mice, then D8 (H2Dd)
transgenic mice, to generate the indicated homozygous Ly49-
knockout (KO) mice on the D8-KODO background.
MHC-restricted, NK cell-dependent resistance to Dm157-
MCMV in D8-KODO mice was absent in DLy49-1 D8-KODO
mice (Figure 2B). Additionally, KODO mice with intact
Ly49s complemented DLy49-1 D8-KODO mice, as their F1 hy-
brids showed fully restored Dm157-MCMV resistance (Fig-
ure 2B), indicating that heterozygous expression of Ly49A,
Ly49C, Ly49G, and Ly49H (Figure S2), deleted in DLy49-1, was
sufficient for resistance. Similarly, (D8-KODO 3 KODO) F1
hybrids were also resistant (Figure 2B), indicating that H2Dd
heterozygosity is sufficient for antiviral protection when Ly49
genes were intact.
Inhibitory Ly49A and Ly49G Receptors Are Required for
H2Dd-Dependent Resistance
To decipher which Ly49 receptor(s) are involved in Dm157-
MCMV resistance in D8-KODO mice, we first considered Ly49
activation receptors. However, a cross between resistant D8-
KODOmice with susceptible B6 (H2b) mice generating heterozy-
gosity for H2Dd and H2b resulted in an intermediate infection
phenotype (Figure 2B), highlighting an apparent role of MHC-I
context for antiviral protection and contrastingMCMV resistance
explained by Ly49 activation receptors when complete reversal
was found in crossing susceptible and resistant mice (Depatie
et al., 1997; Pyzik et al., 2011; Xie et al., 2009). Nonetheless,
as DLy49-1 D8-KODO mice had low levels of Ly49D and lacked
Ly49h, and both receptors require DAP12 (and DAP10 to a lesser
extent) for expression, including Ly49H-mediated resistance to
MCMV, we evaluated the role of Ly49D and Ly49H by studying
D8-KODO mice deficient in DAP10 and DAP12. For reasons
not immediately clear, Ly49A, Ly49F, and Ly49G expression
was markedly decreased (Figure S2). Regardless, these mice
were still resistant (Figure 2C), indicating that activation signals
through DAP10/DAP12 are not required, consistent with the
lack of involvement of NKG2D (Figure 1E), which also requires
DAP10 or DAP12 for surface expression, depending on its iso-
form (Figure S2; Diefenbach et al., 2002). Thus, Ly49 activation
receptors are surprisingly not required for resistance to
Dm157-MCMV in D8-KODO mice.
Having ruled out Ly49 activation receptors, we assessed Ly49
pseudogenes, which could theoretically contribute to resistance
by splicing events, which has been considered for other Ly49
genes (McQueen et al., 1999; Smith et al., 1994). To test
Ly49m (Klra13-ps), harboring a premature stop codon (third
exon), we generated four independent CRISPR-Cas9 KO strains.
When crossed to D8-KODO background, all four lines showed
resistance to Dm157-MCMV, indicating no apparent role for
Ly49m (Figure 2D). Of the other remaining regions of the Ly49
cluster disrupted in the DLy49-1 strain, we did not pursue
Ly49j, Ly49k, and Ly49n, because theywere predicted to encode
severely truncated proteins, not expressed as receptors on NK
cells (McQueen et al., 1999).
We then turned our attention to Ly49 inhibitory receptors. As
Ly49C and Ly49I reportedly have specificity for H2d (Dam
et al., 2003; Hanke et al., 1999), they could be relevant to
DLy49-1 D8-KODO mice, which express Ly49I but not Ly49C
(Figure 2A). However, lack of only these two Ly49s in a new
D8-KODO KO strain had no effect on H2Dd resistance to
Dm157-MCMV, which remained entirely dependent upon NK
cells (Figure 2E).
Finally, we evaluated the potential contribution of Ly49A and
Ly49G, as both are deleted in DLy49-1 mice, and there are sub-
stantial data indicating that they both recognize H2Dd (Jonsson
et al., 2010; Silver et al., 2002). In D8-KODO mice, Ly49A deple-
tion had no significant change in viral titers, while Ly49G deple-
tion moderately increased Dm157-MCMV levels (Figure 3A).
Interestingly, depletion of both Ly49A and Ly49G led to a major
loss of viral control, similar to complete NK cell depletion (Fig-
ure 3A), but Ly49G depletion results in approximately 50%
decrease of all NK cells (Figure S2). Nonetheless, Ly49D deple-
tion, also affecting 50%–60% of NK cells, did not alter viral resis-
tance, suggesting a potential redundant contribution of Ly49A
and Ly49G, independent of quantitative NK cell loss.
To definitively determine the role of Ly49A and Ly49G in resis-
tance, we derived new Ly49 KO strains on the D8-KODO back-
ground (Figures S1 and S2). Although deletion of Ly49A alone
was insufficient to reverse MCMV resistance, Ly49G depletion
in these mice allowed MCMV titers higher than levels with
Ly49G depletion in Ly49A-sufficient mice and similar to that
with NK cell depletion (Figure 3B). Reciprocally, Ly49G-KO
mice were resistant and Ly49A depletion reversed resistance,
again comparable with NK cell depletion (Figure 3C). Finally,
we studied two mouse strains with KOs of both Ly49A and
Ly49G (Ly49AG KO) (Figure S1), which displayed relatively un-
changed NK cell numbers, repertoire of other Ly49s, and devel-
opment (Figure S2). Infection of either Ly49AG-KO strain re-
sulted in viral titers similar to NK cell depletion of D8-KODO
mice (Figure 3D) and lethality (Figure 3E). To provide additional
evidence, we generated Ly49A-knockin (KI) mice (into Ncr1 on
chromosome 7), which expressed Ly49A at near normal levels
on all NKp46+ NK cells (Figure S3). DLy49-1 Ly49A KI D8-
KODO mice demonstrated NK cell-dependent resistance to
Dm157-MCMV, unlike susceptible parental DLy49-1 D8-KODO
mice, showing complementation by Ly49A (Figure 3F). There-
fore, Ly49A and Ly49G act redundantly in H2Dd mice to promote
NK cell-dependent resistance to Dm157-MCMV, unequivocally
establishing the protective role of inhibitory Ly49 receptors in
NK cell-dependent viral control.
NK Cell Licensing and Missing-Self Rejection Both
Require Ly49A and Ly49G Receptors in D8-KODO Mice
To further delineate the potential mechanism for MHC-restricted
viral resistance, we investigated whether loss of Ly49A and
Ly49G would have an impact on NK cell licensing by stimulating
NK cells from D8-KODO, Ly49AG-KO D8-KODO, and TKO
(KODO b2 m/) mice with plate-bound anti-NK1.1 for interferon
gamma production (Kim et al., 2005). Remarkably, the total NK
cell pool in Ly49AG-KO D8-KODO mice exhibited significantly
reduced IFN-gamma production compared with D8-KODO NK
cells and similar to unlicensed NK cells from TKO mice (Figures
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4A and 4B). These results strongly suggest that Ly49A and
Ly49G are required for NK cell licensing through H2Dd.
We next tested whether loss of inhibitory Ly49s would
affect missing-self recognition in vivo, as suggested by
in vitro studies (Bern et al., 2017; Karlhofer et al., 1992) and
anti-Ly49 antibody experiments in vivo (Sun et al., 2012).
Upon injection, labeled KODO (MHC-I-deficient) splenocytes
were effectively cleared in D8-KODO mice that were
either WT or lacked only Ly49A or only Ly49G (Figures 4C
and S4), in an NK cell-dependent manner as shown by NK
cell depletion (Figures S4A and S4B). Importantly, DLy49-1
D8-KODO mice and Ly49AG-KO D8-KODO mice were unable
to reject KODO targets, while complementation of DLy49-1
D8-KODO mice with Ly49A KI restored this capacity. Thus,
these results strongly suggest that Ly49A and Ly49G are
redundant missing-self receptors in D8-KODO mice, as they
enable NK cells to reject missing-self targets through NK
cell licensing.
Figure 3. Ly49G and Ly49A Are Required for H2Dd-Dependent Dm157-MCMV Resistance
(A–D and F) Dm157-MCMV splenic titers; data represent a composite of multiple independent experiments, as noted, with three to seven mice per group, with
individual points representing a single mouse. Mice used were (A) D8-KODO, five experiments; (B) two lines lacking Ly49A (black versus red), three experiments;
(C) Ly49G knockout mice, representative of two experiments; (D) two lines lacking Ly49A and Ly49G, five experiments; and (F)DLy49-1 D8-KODOwith or without
the Ly49A knockin, two experiments.
(E) Composite survival analysis of D8-KODO and Ly49A/G-knockout mice; two experiments.
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Inhibitory Ly49sMediate Protection fromDm157-MCMV
Is ITIM Dependent
We recently generated KI mice carrying Ly49A with a non-func-
tional ITIM (termed Ly49AYF), demonstrating that effector inhibi-
tion and licensing are both mediated by the Ly49A ITIM (Bern
et al., 2017). Ly49AYF D8-KODO mice were resistant to
Dm157-MCMV (Figure 4D) similar to D8-KODO mice, but in
contrast to D8-KODOmice (Figures 3A and 3B), Ly49G depletion
led to significantly elevated viral titers, similar to anti-NK1.1
depletion (Figure 4D). These data also mirror Ly49G depletion
of Ly49A-KO D8-KODO mice (Figure 3B), suggesting that
Ly49A mediates resistance to Dm157-MCMV in an ITIM-depen-
dent manner. We also observed that Ly49G-depleted Ly49AYF
D8-KODO mice were unable to reject missing-self targets, indi-
cating that the ITIM is required for Ly49A to mediate missing-
self recognition in vivo (Figure S4). These findings strongly sug-
gest that Ly49A mediates resistance to Dm157-MCMV in an
ITIM-dependent manner.
MCMV Infection Generates Targets for Missing-Self
Rejection
We next investigated the mechanism by which Dm157-MCMV
might contribute to the Ly49 effects. We initially focused on
two MCMV immunoevasins known to downmodulate MHC-I,
m06 and m152 (Pinto et al., 2006), although they have variable
effects dependent upon MHC-I alleles (Wagner et al., 2002). To
establish their relevance here, we first infected SV40-immortal-
ized D8-KODO mouse embryonic fibroblasts (MEFs) with a
GFP-expressing Dm157-MCMV, indicating that H2Dd was
downregulated in GFP-positive infected cells (Figures 5A and
5B). Next, we produced mutant Dm157-GFP viruses deficient
for m06, m152, or both. Remarkably, H2Dd downmodulation
was completely abrogated only when both m06 and m152
were targeted (Figures 5A and 5B), indicating that m04, an
open reading frame (ORF) previously shown to interact with
MHC-I (Kleijnen et al., 1997), does not play a role in MHC-I regu-
lation for H2Dd. In contrast, WT m152 (Dm06Dm157 MCMV) or
WT m06 (Dm152Dm157 MCMV) decreased surface expression
of H2Dd in infected cells, consistent with virus-free overexpres-
sion systems, demonstrating that both m06 (Reusch et al.,
1999) and m152 (Ziegler et al., 1997) redundantly promote
MHC downregulation.
D8-KODO mice heterozygous for H2Dd (Figure 2B) displayed
H2Dd expression at an MFI of nearly 50% of homozygous
mice (Figure 5C), comparable with the loss seen during in vitro
MCMV infection (Figures 5A and 5B). There was a similar level
of H2Dd expression in (BALB/c3 B6) F1 hybrid mice, confirming
that physiologically relevant levels of H2Ddwere being assessed,
both in vitro and in vivo. Indeed, heterozygous D8 targets in un-
infected homozygous D8-KODO mice were protected from
Figure 4. NK Cell Licensing and Missing-Self Rejection in D8-KODO Mice Both Require Ly49A and Ly49G
(A) Representative histogram plots depicting the frequency of interferon gamma positive (IFNg+) NK cells following NK1.1 stimulation in D8-KODO, Ly49A/G-KO
mice, and TKO (KODO b2 m-KO) mice.
(B) Composite plot of IFNg+ frequencies from (A); two independent experiments with three mice per group.
(C) In vivo cytotoxicity of KODO or D8-KODO splenocytes. Data are cumulative over two independent experiments with four or five recipient mice per group.
(D) Dm157-MCMV infection as in Figure 2B; three independent experiments.
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clearance following a 3 h (Figure 5D) or 24 h (Figure 5E) in vivo
cytotoxicity assay. In contrast, KODO targets were completely
eliminated at both 24 h (Figure 5E) and 48 h (Figure 4C) and
partially eliminated at 3 h after injection (Figure 5D). During
MCMV infection, there was enhanced clearance of both MHC-
null and MHC-heterozygous targets at all times post-infection
(Figure 5D), consistent with our previous study, in whichwe iden-
tified a role for cytokines modulating missing-self rejection
during MCMV infection (Bern et al., 2019). Although heterozy-
gous target cell rejection never reached levels seen with
MHC null targets, NK cell-dependent clearance of missing-self
targets can discriminate between normal levels and partial
downregulation of MHC molecules in the context of MCMV
infection.
Deletion of MCMV Genes m06 and m152 Prevents NK-
Dependent Clearance while Enhancing CD8+ T Cell-
Dependent Protection
To determine ifm06 andm152 perturb NK-dependent viral resis-
tance, we generated an independent set of Dm157-MCMV
stocks in a virulent MCMV strain with mutations in both
m06 and m152, termed Dm157/Dm06/Dm152-MCMV.
Figure 5. Downregulation of H2Dd through m06 and m152 Affects Host MCMV Control
(A) Histogram plots and (B) bar charts of 24 h in vitro infection and flow cytometric evaluation of D8-KODO MEFs with GFP-expressing MCMV lacking the
indicated ORFs; representative of two independent infections.
(C) MFI of H2Dd in mice homozygous and heterozygous for the D8 transgene (left), compared with BALB/c (H2d/d) and BALB/c 3 B6 F1 (H2
b/d) mice (right);
representative of two independent experiments.
(D and E) Three h (D) or 24 h (E) in vivo cytotoxicity with KODO or D8-KODO heterozygous (D8-Het; H2Dd+/) donor cells. Composite data from two independent
experiments.
(F and G) Dm157 or Dm157/m06/m152 MCMV infection of B6 or Rag1/ (F) and D8-KODO or DLy49-1 D8-KODO (G) mice. (F) and (G) are representative titers
from two independent experiments.
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Dm157-MCMV and Dm157/Dm06/Dm152-MCMV showed
similar rates of in vitro growth and viral titers, though Dm157-
MCMV had a slight advantage (Figure S6). Regardless, infection
of Rag1–/– mice on the B6 background indicated that both vi-
ruses had comparable replication in vivo (Figure 5F). By contrast,
Dm157/Dm06/Dm152-MCMV infection of B6 and DLy49-1
D8-KODO mice, otherwise susceptible to Dm157-MCMV
(Figures 1B and 2B), resulted in a resistant phenotype (Fig-
ures 5F and 5G). D8-KODO mice were also resistant to
Dm157/Dm06/Dm152-MCMV, but resistance was not depen-
dent on NK cells (Figure 5G), contrasting their NK cell-dependent
resistance to Dm157-MCMV (Figure 1C). Instead, CD8 depletion
significantly reversed resistance to Dm157/Dm06/Dm152-
MCMV (Figure 5G), unlike the absence of an effect on resistance
to Dm157-MCMV (Figure 1C).
DISCUSSION
Here, we clearly demonstrate that specific NK cell Ly49 inhibitory
receptors have a critical MHC-restricted role in controlling viral
infection in vivo. Their role is dependent on their specificity for
self-MHC-I, which influences their effects on NK cell licensing.
Viral modulation of MHC-I was required because when MHC-I
was no longer downregulated, early resistance was due to
CTLs instead of NK cells. Therefore, both the host (Ly49a and
Ly49g) and the virus (m06 andm152) encode multiple molecules
involved in this resistance, a redundancy highlighting the
ongoing arms race between the host and pathogen and
providing definitive support for the missing-self hypothesis.
In other strains of mice, there are likely differences in the NK
cell response to MCMV due to Ly49 polymorphisms, particularly
their specificities for MHC-I, and receptor repertoire, including
subset distribution. Similarly, hosts may have different MHC-I al-
leles with varying capacities to license NK cells and susceptibil-
ities to downregulation by viral MHC-I inhibitors. These factors
likely account for differences in the MHC-restricted phenotypes
described here. Moreover, there appear to be activation recep-
tors, akin to Ly49H in B6 mice, that may dominate NK cell func-
tion if their ligands are expressed on infected cells, in which case
licensed NK cells may play a secondary role. Finally, MCMV itself
has evolved alleles of its ORFs that modulate these processes.
All of these processes have confounded previous attempts to
clearly elucidate MHC restriction by NK cells.
Our studies suggest that MCMV should encode molecules to
specifically inhibit licensed NK cells. MCMV-encoded m157
can engage Ly49 inhibitory receptors in mouse strains that do
not have Ly49H activation receptor equivalents, such as Ly49I
in 129 mice (Arase et al., 2002) and Ly49C in BALB/c (Pyzik
et al., 2014). We predict that m157 inhibition of NK cell function
will depend on whether these inhibitory receptors are in hosts
with appropriate MHC-I alleles for licensing. Indeed, m157 ef-
fects on inhibiting NK cell control appear to be MHC-dependent
(Pyzik et al., 2014), suggesting such potential interactions. More-
over, MCMV has 11 ORFs with predicted MHC-I folds (Smith
et al., 2002), some of which have been verified by crystallo-
graphic studies (Mans et al., 2007), and thus may be similarly
involved in modulating NK cells. Prior findings have suggested
that in addition to m06 and m152, a third immunoevasin, m04,
also interacts with MHC-I. However, instead of downregulating
MHC-I, m04 stabilizes certain MHC-I alleles on the surface of in-
fected cells recognized by the Ly49A inhibitory receptor in
BALB/c mice (Babic et al., 2010). As an apparent host counter-
measure, m04-MHC-I complexes are recognized by Ly49P, an
activation receptor in MA/My mice, and correlate with NK cell-
dependent resistance to MCMV (Kielczewska et al., 2009).
Nevertheless, although we did not address a potential role for
m04 in our studies, the MHC-I-restricted, inhibitory NK cell re-
ceptor-dependent anti-viral effects described here are funda-
mentally and mechanistically different from prior reports.
Our findings clearly suggest an important role for inhibitory
Ly49 receptors in clearance of MCMV, implying a role for NK
cell activation receptors. Although our studies rule out a role
for activation receptors that require DAP10/12 signaling adap-
tors, such as NKG2D, other activation receptors that do not
require these adaptors may be involved. For example, the acti-
vating receptor DNAM-1 has been described to bind to virus-in-
fected cells via recognition of CD155 and CD112, thereby pro-
moting NK cell-mediated elimination of infected cells (de
Andrade et al., 2014). In addition to DNAM-1 in mice, the natural
cytotoxicity receptor 1 (NCR1/NKp46), 2B4 that engages CD48,
and the lymphocyte function-associated antigen 1 (LFA-1) that
binds ICAM-1 and ICAM-2 (Long et al., 2013) may also play
important roles in missing-self-dependent killing, whether in
the absence or presence of infection. Furthermore, the inflam-
matory milieu, independent of the MHC-I-modulating abilities
of MCMV, could also influence the efficacy of missing-self cyto-
toxicity. Clarification of the involvement of these or additional un-
characterized activation pathways is required to advance our un-
derstanding of these intertwined yet complex pathways.
Beyond viral control, our studies also establish that Ly49 inhib-
itory receptors play a critical role inmissing-self rejection, as pre-
viously predicted, on the basis of in vitro observations and mice
with global defects inMHC-I expression that have unlicensed NK
cells. Here we clearly show that absence of specific inhibitory
Ly49 receptors in a mouse expressing MHC-I results in unli-
censed NK cells and an inability to perform missing-self rejec-
tion. It should be noted that prior studies of Ly49 specificities
were often dependent on overexpression systems that may not
reflect physiological interactions. Understanding of these ambi-
guities will be aided by the Ly49-KOmice described here as well
as complementation by restoring expression of a single Ly49 re-
ceptor. Taken together, these data also provide definitive evi-
dence that the inhibitory receptors are required for missing-self
rejection in vivo.
During the preparation of our manuscript, another group pub-
lished their findings on missing-self recognition using indepen-
dently derived Ly49-KO mice (Zhang et al., 2019). Their experi-
mental evidence supports our claims of the requisite role of
Ly49 receptors in missing-self recognition and confirms the
lack of major perturbations in maturation and expression pat-
terns of other NK cell receptors following CRISPR-mediated de-
letions. However, their work did not address MHC allele speci-
ficity, whereas our work additionally demonstrates that a single
well-defined H2Dd MHC-I molecule is redundantly recognized
by Ly49A and Ly49G in missing-self recognition, while unequiv-
ocally excluding the role of additional Ly49 and NK cell receptors
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in mice expressing only H2Dd. Moreover, our restoration of
missing-self killing using a KI approach using only Ly49A and
abrogation using an ITIM-defective Ly49A further substantiate
the role of inhibitory Ly49s and their ITIMs in missing-self in vivo.
In addition, Gamache et al. (2019) recently studied NK cell
control of MCMV in the MA/My mouse strain, which has a
different Ly49 haplotype fromB6mice (Higuchi et al., 2010) stud-
ied here. Interestingly, recognition of H-2Dk by both the inhibitory
Ly49G2 and the Ly49R activation receptors was required in MA/
My mice for viral control. Although methodological similarities
exist between their findings and ours, some key differences pre-
clude generalization of results. First, we described the viral ORFs
essential for missing-self effects in an MCMV strain that lacks an
important viral ligand for an NK cell activation receptor. More
important, our system clearly delineates that licensing and
missing-self killing are coincident with viral control, whereas
the work by Gamache et al. (2019) describes a mechanism
based on both activation and inhibitory receptors. It is still un-
clear whether these alleles of NK cell receptors in non-B6 strains
function similarly in B6 mice or are significantly influenced by
MHC-dependent and independent factors. These consider-
ations underscore the challenges of relating unique but poten-
tially strain-specific NK cell-mediated effects across all mouse
strains.
Beyond viral clearance, NK cell effects on tumor control
greatly rely on both NK cell activation and inhibitory receptor
signaling (Daher and Rezvani, 2018). MHC-I downmodulation
during tumor growth to evade CTLs provides an attractive target
for oncogenic control, yet the in vivo requirements for this poten-
tial critical function are poorly understood. Indeed, we recently
showed that missing-self rejection in a mouse with inducible
b2 m deletion is markedly enhanced by inflammatory stimuli,
such as MCMV infection, otherwise licensed NK cells can lose
the licensed phenotype when profound MHC-I deletion occurs
(Bern et al., 2019), consistent with results reported here. Thus,
our studies on NK cell control of viral infection, demonstrating
of the complex in vivo interaction between inhibitory receptors
and self-MHC-I, can serve as an analogous framework for
considering how to modulate NK cells for controlling cancer.
Finally, our studies highlight a role for NK cells in MHC-
restricted immune responses, beyond that of MHC-restricted
T cell responses, potentially for human autoimmune diseases
that are associated with specific HLA-I alleles, such as HLA-
B27 and ankylosing spondylitis. Despite the description of this
association several decades ago, its basis is still not understood,
even though it is widely thought to be due to CD8+ T cells (Bow-
ness, 2015). Our studies suggest that NK cells may also play an
important role in this and other HLA-I disease associations.
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CD122 Monoclonal Antibody (TM-b1 (TM-beta1)),
eFluor 450
eBioscience/Thermo Fisher Scientific Cat# 48-1222-82; RRID: AB_2016697
CD314 (NKG2D) Monoclonal Antibody (CX5), PE eBioscience/Thermo Fisher Scientific Cat# 12-5882-82; RRID: AB_465996
CD335 (NKp46) Monoclonal Antibody (29A1.4),
PerCP-eFluor 710
eBioscience/Thermo Fisher Scientific Cat# 46-3351-80; RRID: AB_1834442
Anti-Mouse Ly49H (3D10) APC antibody eBioscience/Thermo Fisher Scientific Cat# 17-5886-80; RRID: AB_10596369
Rat Anti-Mouse CD127 (SB/199) Monoclonal
Antibody, PE-Cy7
BD Biosciences Cat# 560733; RRID: AB_1727424
Anti-mouse NK-1.1 (PK136) antibody,
Brilliant Violet 650
Biolegend Cat# 108736; RRID: AB_2563159
Anti-mouse NK-1.1 (PK136) antibody,
PerCP-Cy5.5
eBioscience/Thermo Fisher Scientific Cat# 45-5941-82; RRID:AB_914361
Anti-mouse NKG2A B6, Biotin eBioscience/Thermo Fisher Scientific Cat# 13-5897-85; RRID: AB_466781
Anti-mouse NKG2D (CD314, CX5), PE eBioscience/Thermo Fisher Scientific Cat# 12-5882-82; RRID: AB_465996
Anti-mouse Ly49F (HBF-719), PE Thermo Fisher Scientific Cat# MLY49F04; RRID: AB_2539785
Anti-Mouse Ly49E/F PerCP-eFluor 710 eBioscience/Thermo Fisher Scientific Cat# 46-5848-80; RRID: AB_2016642
Anti-Mouse Ly49A (JR9), Biotin Hybridoma provided by Jacques Roland
(Roland and Cazenave, 1992)
Biotin labeled in lab
Anti-Mouse Ly49C (4LO3311), Biotin Hybridoma provided by Suzanne Lemieux
(Brennan et al., 1996)
Biotin labeled in lab
Purified anti-mouse NK1.1 antibody (PK136) Purified from PK136 Hybridoma,
American Type Culture Collection, ATCC
Cat# HB-191; RRID: CVCL_7695
Fc Receptor blocking antibody, 2.4G2 Purified from 2.4G2 Hybridoma,
American Type Culture Collection, ATCC
Cat# HB-197; RRID: CVCL_9148
Anti-mouse CD27 Antibody (LG.7F9), APC eBioscience/Thermo Fisher Scientific Cat# 17-0271-82; RRID: AB_469370
Anti-mouse CD11b Antibody (M1/70), eFluor 450 eBioscience/Thermo Fisher Scientific Cat# 48-0112-82; RRID: AB_1582236
Anti-mouse CD69 Antibody (H1.2F3), eFluor 450 eBioscience/Thermo Fisher Scientific Cat# 48-0691-82; RRID: AB_10719430
Anti-mouse Ly49G2 Antibody (4D11), APC BD Biosciences Cat# 555316; RRID: AB_398590
Anti-mouse Ly49D Antibody (4E5), APC eBioscience/Thermo Fisher Scientific Cat# 17-5782-82; RRID: AB_10717290
Anti-mouse Ly49I Antibody (YLI-90), Biotin Abcam Cat# ab25203; RRID: AB_448709
Anti-mouse CD94 Antibody (18d3), eFluor 450 eBioscience/Thermo Fisher Scientific Cat# 48-0941-82; RRID: AB_11218905
Anti-mouse CD244.2 (2B4) Antibody
(eBio244F4), PE-Cy7
eBioscience/Thermo Fisher Scientific Cat# 25-2441-82; RRID: AB_2573432
Anti-mouse IFN gamma Antibody
(XMG1.2), eFluor 450
eBioscience/Thermo Fisher Scientific Cat# 48-7311-82; RRID: AB_1834366
Anti-mouse H-2Dd antibody (34-2-12), PE Biolegend Cat# 110608; RRID: AB_313489
Anti-mouse H-2Dd antibody (34-2-12),
Alexa Fluor 647
Biolegend Cat# 110612; RRID: AB_492913
Anti-mouse CD8a antibody (53-6.7), FITC eBioscience/Thermo Fisher Scientific Cat# 11-0081-86; RRID: AB_464917
Streptavidin-Phycoerythrin BD Biosciences Cat# 554061; RRID: AB_10053328
Streptavidin-Allophycocyanin Biolegend Cat# 405207
(Continued on next page)
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Purified Ly49G (LGL-1) antibody Purified from hybridoma Rheumatic
Diseases Core Center Protein
Purification and Production Facility
(Washington University)
(Mason et al., 1988)
Purified Ly49D (4E4) antibody Purified from hybridoma Rheumatic
Diseases Core Center Protein
Purification and Production Facility
(Washington University)
(Idris et al., 1999)
Purified Ly49H (3D10) antibody Purified from hybridoma Rheumatic
Diseases Core Center Protein
Purification and Production Facility
(Washington University)
(Smith et al., 2000)
Purified CD8a (YTS-169) antibody BioXCell Cat# BE0117, RRID:AB_10950145
Bacterial and Virus Strains
Dm157 MCMV (Parikh et al., 2015b) N/A
Dm157 MCMV, green fluorescent
protein (GFP) reporter
(Henry et al., 2000) N/A
Dm157/Dm06 MCMV (GFP) This study N/A
Dm157/Dm0152 MCMV (GFP) This study N/A
Dm157/Dm06/Dm0152 MCMV (GFP) This study N/A
Dm157/Dm06/Dm0152 MCMV This study N/A
Wild-type murine cytomegalovirus (MCMV) (Cheng et al., 2010) Genebank Accession GU305914
Chemicals, Peptides, and Recombinant Proteins
Fixable Viability Dye eFluor 506 eBioscience Cat# 65-0866-14
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich Cat# P8139
Ionomycin, calcium salt Sigma-Aldrich Cat# I0634
Cytofix/perm kit with Brefeldin A (GolgiPlug) BD Biosciences Cat# 555028
Critical Commercial Assays
mMESSAGE mMACHINE T7 Ultra
Transcription Kit
Thermo Fisher Scientific Cat# AM1345
MEGAclear Transcription Clean-Up Kit Thermo Fisher Scientific Cat# AM1908
CellTrace CFSE Cell Proliferation Kit Thermo Fisher Scientific Cat# C34554
CellTrace Violet Cell Proliferation Kit Thermo Fisher Scientific Cat# C34557
MEGAshortscript T7 Transcription Kit Thermo Fisher Scientific Cat# AM1354
Experimental Models: Cell Lines
Cells: BALB/3T12-3 fibroblasts American Type Culture
Collection, ATCC
Cat# CCL-164, RRID:CVCL_0637
Cells: SV40-immortalized B6 murine
embryonic fibroblasts (MEFs)
This study E12.5 MEFs from C57BL/6NCrl mice
Cells: SV40-immortalized D8-KODO MEFs This study E12.5 MEFs from D8-KODO mice
Experimental Models: Organisms/Strains
Mouse: C57BL/6NCrl Charles River Laboratories Cat#027, RRID:IMSR_CRL:027
Mouse: BALB/cAnNCrl Charles River Laboratories Cat# CRL:028, RRID:IMSR_CRL:028
Mouse: Klra7em1(IMPC)J (Ly49G KO) The Jackson Laboratory
(now at MMRRC)
Cat# MMRRC:048353-UCD
Mouse: C57BL/10SnJ (B10) The Jackson Laboratory IMSR Cat# JAX:000666,
RRID:IMSR_JAX:000666
Mouse: B10.D2/nSnJ (B10.D2) The Jackson Laboratory IMSR Cat# JAX:000463,
RRID:IMSR_JAX:000463
Mouse: H2Kb/ H2Db/ (KODO) Taconic Farms IMSR Cat# TAC:4215,
RRID:IMSR_TAC:4215
(Continued on next page)
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Mouse: Prf1/ The Jackson Laboratory IMSR Cat# JAX:002407,
RRID:IMSR_JAX:002407
Mouse: Rag1/ The Jackson Laboratory IMSR Cat# JAX:002216,
RRID:IMSR_JAX:002216
Mouse: DAP10/, DAP12/ Provided by T. Takai (Inui et al., 2009)
Mouse: NKG2D/ (KLRK1 KO) Provided by Bojan Polic
(University of Rijeka, Croatia)
(Zafirova et al., 2009)
Mouse: H2Kb/ H2Db/, b2 m/ Obtained from Ted Hansen
(Washington University, St. Louis)
N/A
Mouse: D8-B6 (transgenic mice expressing H2Dd) Provided by D. Marguiles
(National Institute of Allergy and
Infectious Diseases, Bethesda, MD)
N/A
Mouse: D8-KODO (H2Kb/ H2Db/ mice
expressing H2Dd transgene)
Previously generated in lab (Choi et al., 2011)
Mouse: GzmB/ (Granzyme B KO) Obtained from T. Ley (Washington
University, St. Louis)
(Heusel et al., 1994)
Mouse: D8-KODO AYF (ITIM mutant of Ly49A) Previously generated in lab (Bern et al., 2017)
Mouse: Ly49A/ (strain A15) This study N/A
Mouse: Ly49A/ (strain A20) This study N/A
Mouse: Ly49C/, Ly49I/ (strain C14B) This study N/A
Mouse: Ly49M/ (strains M1, M4, M7, M8) This study N/A
Mouse: Ly49A/, Ly49G/ (strain AG1) This study N/A
Mouse: Ly49A/, Ly49G/ (strain AG7) This study N/A
Mouse: Ly49A/, Ly49C/ Ly49H/, Ly49G/
(strain DLy49-1)
This study N/A
Mouse: Ly49A knockin into NKp46 locus (Ly49A-KI) This study N/A
Oligonucleotides
Guide RNA for MCMV disruption See Table S3 All oligonucleotides were synthesized
by IDT (Coralville, IA)
Primers for Ly49 sequence analysis See Table S4 All oligonucleotides were synthesized
by IDT (Coralville, IA)
Primers for MCMV sequence analysis See Table S5 All oligonucleotides were synthesized
by IDT (Coralville, IA)
Guide RNA for Ly49 disruption See Table S1 All oligonucleotides were synthesized
by IDT (Coralville, IA)
Primers for MCMV quantification Generated previously in lab (Parikh et al., 2015b)
Recombinant DNA
p2A-Ly49A cDNA cassette This study GeneBlock synthesized at IDT and
inserted into NKp46 genomic
DNA in pACYC177
pCDNA3.1 Mammalian Expression Vector Thermo Fisher Scientific Cat# V79020
Plasmid pX330-U6-Chimeric_BB-CBh-hSpCas9 (Ran et al., 2013) RRID:Addgene_42230
SV40 1: pBSSVD2005 Addgene RRID:Addgene_21826
Plasmid pACYC177 New England Biolabs Cat # E4151
Software and Algorithms
SnapGene software GSL Biotech Version 4.3
FlowJo Software BD Biosciences v10.1 for Windows
CCTop https://crispr.cos.uni-heidelberg.de/ (Stemmer et al., 2015)
ABI StepOnePlus qPCR software Applied Biosystems Version 2.3
GraphPad Prism GraphPad Software Version 8.2.1 for Windows
GT-Scan https://gt-scan.csiro.au/gt-scan (O’Brien and Bailey, 2014)
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact author
Wayne M. Yokoyama (yokoyama@wustl.edu).
Materials Availability
All viruses and mouse lines developed for this study are available under Material Transfer Agreements from Washington University
School of Medicine.
Data and Code Availability
The published article includes all data generated or analyzed during this study. Original source data for Figures in the paper are avail-
able upon request to the Lead Contact author. No proprietary software was used in the data analysis.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
C57BL/6Ncr (B6) and BALB/cAnNCr (BALB/c) mice were purchased from Charles River Laboratories. C57BL/10SnJ (B10; 000666),
B10.D2/nSnJ (B10.D2; 000463), Prf1/ (002407) and Rag1/ (002216) strains were purchased from Jackson Laboratory.
DAP10/DAP12/ mice were provided by T. Takai (Inui et al., 2009). NKG2D/ (Klrk1/) mice were obtained from Bojan Polic
(University of Rijeka, Croatia) (Zafirova et al., 2009). Granzyme B KO (GzmB/) mice were obtained from T. Ley (Washington Uni-
versity, St. Louis) (Heusel et al., 1994). H2Kb/ H2Db/ (KODO) mice were purchased from Taconic Farms. Triple knockout (TKO)
micewhich are H2Kb/H2Db/ and lack b2mwere obtained from T. Hansen (WashingtonUniversity, St. Louis). D8 transgenicmice
expressing an H2Dd genomic construct (Bieberich et al., 1986) were provided by D. Marguiles (National Institute of Allergy and In-
fectious Diseases, Bethesda, MD). D8-KODO mice were generated by crossing D8-transgenic mice to KODO mice (Choi et al.,
2011). Generation and characterization of the ITIM mutant AYF mice on the H2d background have been previously described
(Bern et al., 2017). KLRA7em1(IMPC)J (Ly49G KO) mice on the C57BL/6NJ background were purchased from the Jackson Laboratory
(027444); this allele was generated at the Jackson Laboratory by CRISPR-Cas9 injection of Cas9 RNA and 3 gRNAs:
TCTTGTACTTGTGCATAACC, CAGTCCTCACTAGTTTCTGC and GACATGGACTGACCAAATT resulting in a 241 bp deletion begin-
ning in 5-prime upstream sequence and ending within exon 1. Additional strains of mice generated through CRISPR-Cas9 are
described below. All mice, with the exception of the Rag1/ strain, used in these studies were initially obtained or generated on
the B6 genetic background and later backcrossed to the KODO and then D8-KODO background (H2Dd MHC). B6 mice used in ex-
periments were obtained directly from Charles River Laboratories. All other experimental and control mice were bred in-house at
Washington University. Mice were 8–14-wk old at the start of experiments unless otherwise stated. Male and/or female mice
were used in individual experiments without blinding or randomization. This study was carried out in strict accordance with the rec-
ommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The studies were
approved by the Animal Studies Committee at Washington University School of Medicine under animal protocol 20180293.
Development of CRISPR-modified knockout mice
While NCBI BLAST (https://blast.ncbi.nlm.nih.gov/) was initially used to assess sequence similarity of potential sgRNAs, GT-Scan
(https://gt-scan.csiro.au/gt-scan) (O’Brien and Bailey, 2014) and CCTop (https://crispr.cos.uni-heidelberg.de/) (Stemmer et al.,
2015) were primarily used to confirm the correct and specific targeting our sgRNA designs. The sequences of synthetic guide
RNAs (sgRNA) and the strains of mice generated are shown in Table S1. Cas9 mRNA and sgRNA synthesis, RNA micro-injection
into zygotes is identical to what we described earlier (Parikh et al., 2015a). Specifically, we used 20ng of each guide when multiple
guides were indicated, and 100ng of Cas9 mRNA. Pups were screened for Ly49 gene disruption at birth by PCR. If multiple Ly49
alleles were present, they were separated by one backcross to B6 and re-screened by PCR. All mice with in-frame insertions or de-
letions (indels) were excluded from further analysis. Multiple lines with out-of-frame indels were chosen for downstream character-
ization. These genetic lesions were verified by absence of PCR amplicons for each of the indicated Ly49 genes in homozygous mice,
and specific PCR amplicons for the deleted genomic regions, that were sequenced to determine the exact breakpoints (Figures S1
and S2). Finally, Ly49 protein expression was examined, where antibodies were available, at 8 weeks in homozygous mice following
at least one additional backcross to parental B6. Since all sgRNAs targeted the second exon of Ly49 genes, we focused on this exon
to specifically interrogate on-target and off-target analysis. As shown in Figure S1, all exons and the sgRNA with on-target and off-
target potential are depicted. Sanger sequence traces of homozygous mice are shown below the schematic. Flow analysis across
genes expressed within the NKC in D8-KODO mice is presented as Figure S2. Specifically, we generated Ly49C/I-double-deficient
mice (two lines; one used in experiments), Ly49m-deficient mice (four lines used in experiments), Ly49A-deficient mice (two lines
used in experiments), Ly49A/G-double-deficient mice (two lines used in experiments), and the DLy49-1 D8-KODO multi-deficient
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mice (one line used in experiments). The Ly49G-deficient micewere purchased from Jackson Laboratory, however, full on-target, off-
target (Figure S1) and flow cytometric (Figure S2) analyses was performed by our laboratory. Importantly, no major impact on matu-
ration was observed in any of these mice.
Development of CRISPR-modified Ly49A knockin mice
The NKp46 (Ncr1) locus was chosen for insertion of the Ly49A cDNA (Figure S3). The donor construct was designed to replace the
stop codon of NKp46 (while maintaining the 3-prime untranslated region) with a P2A peptide-cleavage site upstream of the Ly49A
cDNA obtained from reverse transcription of Ly49A-expressing B6 NK cells. The result is that Ly49A expression would be
restricted to all NK cells. Given that the Ly49A knockin is located on chromosome 7, we were able to cross this mouse with the
DLy49-1 mouse with Ly49 deletions on chromosome 6 without linkage restrictions. GT-Scan (O’Brien and Bailey, 2014) and
CCTop (Stemmer et al., 2015) were primarily used to confirm the correct and specific targeting our sgRNA to the NKp46 locus.
The sequences of guide RNAs are shown in Table S1. Cas9 mRNA and sgRNA synthesis, RNA and donor DNA micro-injection
is identical to what we described earlier (Parikh et al., 2015a). Specifically, we used 10ng of donor DNA, 20ng of each guide (2 total),
and 100ng of Cas9 mRNA. Pups were screened for the donor DNA by PCR soon after birth and maintained as heterozygotes for
flow-based confirmation at 8 weeks. After two rounds of B6 backcrossing, the mice were bred to DLy49-1 D8-KODO. Mice homo-
zygous for the NKC deletion but heterozygous for the Ly49A knockin were screened for expression of Ly49A (Figure S3). Subse-
quently, various NKC surface molecules were analyzed by flow cytometry (Figure S2). Again, no major impact on maturation was
observed.
Development of CRISPR-Cas9 modified MCMV
Dm157-MCMV and GFP-expressingMCMVweremodified to knockout various viral ORFs using CRISPR-Cas9 editing to obviate the
need for bacterial artificial chromosome modification. The GFP-expressing MCMV was a generous gift from S.C. Henry and J. Ham-
ilton (Duke University, Durham, NC, USA) (Henry et al., 2000) and previously described by our lab to harbor a non-functional m157
gene (Hsu et al., 2009). The GFP-expressing MCMV and CRISPR-derived progeny were used in in vitro studies while the Dm157-
MCMV derived fromWT1 (Cheng et al., 2010) and its CRISPR-modified progeny were used in the in vivo analyses. CCTop (Stemmer
et al., 2015) was used to identify and confirm specific targeting our sgRNAs to the MCMV ORFs. The stand-alone version of CCTop
was loaded with the MCMV genome (GenBank Accession GU305914.1) to effectively eliminate off-target cleavage potential. The ta-
ble of all possible guide site forMCMV is provided (Table S2). The pX330 vector (Cong et al., 2013; Ran et al., 2013) was obtained from
Addgene and modified by replacing the SbfI-PsiI site with the Neo marker (SbfI-HincII fragment) from pCDNA3. The oligonucleotide
duplexes containing single sgRNAs specific for MCMV m06 or m152 (Table S3) were cloned into this vector that was subsequently
transfected into SV40-immortalized B6MEFswith G418 selection. Parental virus was used to infect these sgRNA andCas9-express-
ingMEFs at a lowMOI (0.1). Once confluent lysis was observed, viral supernatants were used to reinfect B6MEFs, individual plaques
were picked, and sequence variants were confirmed (Figure S5). For double-deficient MCMV ORF knockouts, a pure stock of virus
(e.g.,m06 knockout) was used to infect MEFs expressing Cas9 and the alternate sgRNA of interest (e.g.,m152). For in vivo analysis,
plaque-purified virus was used to generate salivary gland passaged stocks in BALB/c mice as described above. Salivary gland-
derived MCMV lacking m06, m152, and m157 was compared to MCMV lacking m157 in a multi-step growth curve on NIH 3T12
(ATCC CCL-164) fibroblasts (MOI = 0.1). Viral genome copies quantified from cell lysates and culture supernatants, as previously
described (Parikh et al., 2015b), demonstrated that replication of the triple knockout virus was unimpaired yet delayed slightly in over-
all growth (Figure S6).
METHOD DETAILS
Viral infection and quantification
The salivary gland propagatedMCMV stocks were generated from purified and sequenced clones. Virus was inoculated via the intra-
peritoneal (IP) route in a total volume of 200 mL PBS at a dose of 40,000 plaque forming units (pfu) per mouse for WT-MCMV and
20,000 pfu per mouse for m157-deficient MCMV (Parikh et al., 2015b) (Dm157-MCMV) and Dm157/m06/m152-MCMV for determi-
nation of splenic titers at day 4. Viral titers from infected spleens were quantified as a ratio of MCMV IE DNA to host beta-actin DNA
using real-time PCR and Taqman probes as previously described (Parikh et al., 2015b).When shown, individual data points represent
a single mouse. Survival analysis endpoints were determined as either death or >20% weight loss from starting weights, using
300,000 pfu of Dm157-MCMV per mouse. To examine H2Dd MHC-I downmodulation, SV40-immortalized D8-KODO MEFs were in-
fected with GFP-expressing MCMV at anMOI of 1 for 24 h and subsequently released from plates with Versene (Thermo Fisher, Wal-
tham, MA) prior to antibody staining and flow cytometric analysis.
Antibody depletions
Purified 3D10 (a-Ly49H) (Smith et al., 2000), PK136 (a-NK1.1), JR9 (a-Ly49A), 4E4 (a-Ly49D )(Idris et al., 1999), LGL-1 (a-Ly49G) (Ma-
son et al., 1988) and YTS-169 (a-CD8a) were obtained from hybridomas purified by the Rheumatic Diseases Core Center Protein
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Purification and Production Facility (Washington University). Antibodies were injected IP at a dose of 200 mg per mouse 48 h prior to
infection. >98% depletion was confirmed via flow cytometry in a subset of treated mice. Injection of PBS alone was used as a control
where indicated.
Antibodies and Flow Cytometry
The following antibodies and reagents were purchased from eBioscience: anti-CD3e (145-2C11), anti-CD19 (eBio1D3), anti-NK1.1
(PK136), anti-NKp46 (29A1.4), anti-CD27 (LG.7F9), anti-CD11b (M1/70), anti-Ly49D (eBio4E5), anti-Ly49E/F (CM4), anti-Ly49G2
(eBio4D11), anti-Ly49H (3D10), anti-Ly49I (YLI-90), anti-CD94 (18d3), anti-NKG2AB6 (16a11), anti–IFN-g (XMG1.2), anti-CD122
(5H4), anti-CD127 (SB/199), anti-CD69 (H1.2F3), anti-2B4 (2B4), anti-NKG2D (CX5) and Fixable Viability Dye eFluor 506. The
following antibodies and reagents were purchased from BD Biosciences: anti-Ly49F (HBF-719), anti-Ly49G2 (4D11), and streptavi-
din (SA)-phycoerythrin. The following antibodies and reagents were purchased from BioLegend: anti-NK1.1 (PK136), anti-H2Dd (34-
2-12) and SA-allophycocyanin. Anti-Ly49I (YLI-90) was purchased from Abcam. Anti-Ly49A (JR9) was purified in our laboratory from
hybridoma supernatants and subsequently conjugated to biotin. The JR9 hybridoma was generously provided by Jacques Roland
(Pasteur Institute, Paris, France) (Roland and Cazenave, 1992). Anti-Ly49C (4LO3311) (Brennan et al., 1996) was purified in our lab-
oratory from hybridoma supernatants and subsequently conjugated to biotin. The 4LO3311 hybridoma was generously provided by
Suzanne Lemieux (Institut National de la Recherche Scientifique-Institut Armand-Frappier, Laval, Quebec, Canada). Anti-NK1.1
(PK136) was purified in our laboratory from hybridoma supernatants. The PK136 hybridomawas purchased fromAmerican Type Cul-
ture Collection. Fc receptor blocking was performed with 2.4G2 (anti-FcgRII/III) hybridoma (American Type Culture Collection) cul-
ture supernatants. Surface staining was performed on ice in staining buffer (1% BSA and 0.01% NaN3 in PBS). Samples were
collected using a FACSCanto (BD Biosciences), and data were analyzed using FlowJo v10.1 for Windows (BD Biosciences).
In vivo cytotoxicity
Mice used for donor splenocytes in in vivo cytotoxicity assays were 8–12 weeks old at the time of transfer. WT-MCMV, where indi-
cated, was inoculated 3 days prior at a dose of 10,000 pfu per mouse (Parikh et al., 2015b). Donor splenocytes were harvested and
labeled in vitro with 2.5 mM CFSE (Thermo Fisher) and 5 or 0.2 mM CellTrace violet (CT violet; Thermo Fisher). Recipient mice were
injected intravenously with 2 3 106 of each donor. Spleens from recipient mice were harvested 3 (Figure 5B), 24 (Figure 5C) or 48
(Figure 4C; Figure S4) h after transfer of donor cells. NK cell-specific rejection was calculated by gating on transferred CFSE-positive
cells and excluding dead cells by forward scatter and side scatter. Rejection was quantified as Killing Percentage = [1 (Target/Con-
trol)/(Target/Control)Average(NK depleted)] 3 100, where the target was the MHC-deficient (H2Dd/)or heterozygous (H2Dd+/)
donor cell and the control was a H2Dd+/+ donor cell. The ratio of target to control cells was normalized to the average ratio recovered
from NK cell-depleted mice to calculate rejection by NK cells.
NK cell stimulation and intracellular staining
Splenocytes were stimulated with anti-NK1.1 (PK136) as previously described (Kim et al., 2005). Briefly, 24-well culture plates were
coatedwith 500 mL of purified PK136 (1 mg/mL). Plates werewashedwith PBS, and 53 106 splenocytes were then added to eachwell
in 500 mL of R10 (RPMI 1640 supplemented with 10% fetal bovine serum) media. Splenocytes were stimulated in parallel with 0.5 mg/
mL PMA (Sigma-Aldrich) and 4 mg/mL ionomycin (Sigma-Aldrich) and incubated at 37C and in 5% CO2 for a total of 7 h. Brefeldin A
(GolgiPlug; BD Biosciences) was added to the cells after 1 h. After staining surface antigens, cells were fixed and permeabilized (Cy-
tofix/Cytoperm; BD Biosciences) followed by staining for IFN-g. NK cells were gated as viable CD3 CD19 NKp46+ lymphocytes.
Sequence analysis
PCR ampliconswere amplifiedwith the Phusion high-fidelity DNA polymerase (NEB, Ipswich, MA) usingmanufacturer recommended
cycling conditions, column purified (Macherey-Nagel, Bethlehem, PA) and were sequenced on an ABI 3730 at Genewiz, Inc (South
Plainfield, NJ, USA). The resulting chromatograms were aligned using SnapGene software (GSL Biotech, Chicago, IL) and the rele-
vant reference sequences for MCMV (GenBank Accession GU305914.1) or the C57BL/6 (GRCm38/mm10). All oligonucleotides were
synthesized by IDT (Coralville, IA).
QUANTIFICATION AND STATISTICAL ANALYSIS
Significance for all statistical tests was determined at p values < 0.05 and is shown as ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05,
ns = not significant in all figures. All data were assessed for normality using probability plots and the Kolmogorov-Smirnov test
for normality (GraphPad Prism v8.2.1). Normal distributions of viral load, flow cytometry frequencies, and survival analysis
were compared using either two-tailed Student’s t test (2 analyzed groups) or one-way ANOVA (> 2 analyzed groups) and corrected
for multiple comparison using the Bonferroni method (GraphPad Prism v8.2.1). Killing percentages were treated as non-normal
data and compared using Mann-Whitney U (2 analyzed groups) or Kruskal-Wallis (> 2 analyzed groups) tests and corrected for
multiple comparison using Dunn’s method (GraphPad Prism v8.2.1). Error bars in all figures represent the standard error of the
mean (SEM).
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Supplementary Figure Legends 
Figure S1. Characterization of on-target and off-target CRISPR deletions targeting specific Ly49 genes. 
Genomic DNA was isolated from back-crossed H2Dd CRISPR-Cas9 modified mice used in these studies. 
The specific CRISPR-targeted exons (those with homology to the ITIM) were Sanger sequenced as 
representative of the most likely position of off-target effects and to confirm and characterize the 
frameshift in on-target variants. The primers used for PCR and subsequent sequence analysis are shown 
in Table S4. (A-P) Each panel depicts the reference sequence (above), the region of the exon targeted (in 
blue), the on-target and off-target guide sites (in purple), and the Sanger alignments (below) for the 
mice indicated. Mice are designated as to which strains (in parentheses) were analyzed. B6 is the wild-
type genome for comparison. Red boxes indicate indels (inserted nucleotides are shown, while deleted 
bases are represented as a dash). Sequence analysis was confirmed in both the forward and reverse 
directions, however, for clarity only one direction is shown. Sequences assessed in each panel are as 
follows: (A) Klra1/Ly49a, (B) Klra2/Ly49b, (C) Klra3/Ly49c, (D) Klra4/Ly49d, (E) Klra5/Ly49e, (F) 
Klra6/Ly49f, (G) Klra7/Ly49g, (H) Klra8/Ly49h, (I) Klra9/Ly49i, (J) Klra10/Ly49j, (K) Klra11-ps/Ly49k, (L) 
Klra13-ps/Ly49m, (M) Klra14/Ly49n, (N) Klra17/Ly49q, (O) Gm6548, and (P) Gm15854/Ly49x. (Q) 
Nucleotide level analysis of the ΔLy49-1 deletions for the haplotype corresponding to Figure 2A at the 
Ly49g-Ly49a and Ly49n-Ly49k junctions. Related to Figure 2A. 
 
Figure S2. Flow cytometric characterization of CRISPR-Cas9 modified mice. 
Offset flow histograms are shown for mice on the D8-KODO (H2Dd) MHC background with the indicated 
CRISPR-Cas9 modifications. Single-cell suspensions of mouse splenocytes were gated for expression of 
specific proteins with loci near or in the NKC. (A-O) Shown is a representative plot of 
NK1.1+/NKp46+/CD19-/CD3- lymphocytes. Protein levels assessed in each panel are as follows: (A) Ly49A, 
(B) Ly49C, (C) Ly49D, (D) Ly49EF, (E) Ly49F, (F) Ly49G, (G) Ly49H, (H) Ly49I, (I) CDD94, (J) NKG2A, (K) 
NKG2D, (L) CD69, (M) CD122, (N) CD127 and (O) 2B4. The flow cytometric analyses were repeated twice 
with 3 mice per group. Below the plots, quantification of the flow data as frequencies (A-J) or MFI (K-O) 
from one of two representative experiments is provided. (P) Representative maturation plots are shown 
for all experimental mice with the summation of a representative experiment provided at the bottom. 
No significant deviations were noted. Analyses were repeated twice with 3 mice per group. (Q) 
Quantification of NK cell frequencies gated as CD3-CD19-NK1.1+ lymphocytes. (R) Flow cytometric 
analysis of mice heterozygous for the ΔLy49-1 D8-KODO KO (F1 hybrids of KODO mice with intact Ly49s 
and ΔLy49-1 D8-KODO mice from Fig2B) compared with KO and WT mice. Experiments were performed 
twice with 5-7 mice per group, with the exception that WT mice were assessed only once in this panel 
with values consistent with panels above. (S) Flow cytometry gating strategy. For all  flow cytometry 
data, statistical analyses was performed using one-way ANOVA  and corrected for multiple comparison 
using the Bonferroni method with D8-KODO expression or MFI as a comparator; ****p < .0001, ***p < 
.001, **p < .01, *p < .05. Related to Figures 2 and 4. 
 
Figure S3. Strategy and characterization of the NKp46-Ly49A knockin. 
(A) CRISPR knockin strategy for Ly49A expression on NKp46-expressing cells. 2 CRISPR guides, T1 and T3 
(Table S1) were injected into B6 zygotes along with Cas9 mRNA and a donor DNA construct engineered 
to express the Ly49A cDNA following a P2A cleavage site such that the Ly49A expression would be 
proportional to NKp46 (Ncr1) transcript levels. (B) The final NKp46 TGA stop codon and several 
downstream bases (yellow highlighted region) in the coding region of exon 7 (blue text) were removed 
and replaced with a P2A site (purple text), Ly49A cDNA (red text) and finally the remainder of the NKp46 
3’ UTR sequence (green text). This donor vector with NKp46 homologous arms was co-injected with 
sgRNA for Ncr1 and Cas9 into B6 zygotes and positive knockin mice were selected at birth by PCR 
analysis and confirmed at 6 weeks of age by flow cytometry. (C) One Ly49A KI line was crossed to the 
ΔLy49-1 D8-KODO mice (Figure 2A) heterozygous for one knockin allele and confirmed by flow 
cytometry. Lymphocytes for splenic single cell suspensions were assessed for both NK1.1 and Ly49A 
expression. Approximately 18% of NK cells from WT (D8-KODO) mice expressed Ly49A, while the ΔLy49-
1 D8-KODO mice lacked all Ly49A expression unless expressing the Ly49A from the knockin construct 
(nearly 100% expression). As shown, Ly49A expression was restricted to NK1.1+ splenocytes. Related to 
Figures 3F and 4C. 
 
Figure S4. In vivo cytotoxicity in Ly49AG KO and Ly49AYF mice. 
In vivo cytotoxicity of MHC-I deficient (KODO) or sufficient (D8-KODO) splenocytes following differential 
labelling with Celltrace Violet and flow cytometric analysis recovered from spleens at 2 days post-
injection. (A) Flow cytometric analysis of input cells is shown (prior to injection). The experimental 
design is also depicted with the timing of antibody depletion relative to injection and harvest. (B) 
Representative histogram plots of the mice indicated in each row and treatments by column. The peaks 
are identified by the input plot shown in (A). (C) Quantification was performed as previously described 
(Figure 4C). Data are representative of two independent experiments with three recipient mice per 
group that received the same mix of donor cells in each experiment. Standard error of the mean is 
shown; statistical analysis performed using one-way ANOVA  and corrected for multiple comparison 
using the Bonferroni method; *p < .05, ****p < .0001. Related to Figure 4. 
 
Figure S5. Sanger sequence analysis of m06 and m152 in CRISPR-modified MCMV strains. 
Viral DNA was isolated from in vitro cell cultures infected with CRISPR-Cas9 modified MCMV used in 
these studies. The specific CRISPR-targeted ORFs, (A) m06 and (B) m152, were Sanger sequenced to 
confirm and characterize the frameshift in on-target variants. The primers used for PCR and subsequent 
sequence analysis are shown in Table S5. Each panel depicts the reference sequence above with the 
region of the ORF expanded for analysis. The Sanger alignments below for the viruses indicated are 
designated as to which strains (left of trace) were analyzed. Δm157-MCMV is the wild-type genome at 
these ORFs, for comparison. Red boxes indicate where inserted nucleotides were identified. Sequence 
analysis was confirmed in both the forward and reverse direction, however, only one direction is shown 
for clarity. Related to Figure 5. 
 
Figure S6. Multi-step growth curve 
Multi-step in vitro growth kinetics of two strains of MCMV, as indicated. Cells and supernatants were 
harvested at the indicated days and quantified by real-time PCR. Data is a representative of two 
independent experiments with each data point performed in triplicate. All timepoints were shown to 
significantly different in terms of viral load (p < .0001); statistical analysis performed with a Student’s t-
Test. Related to Figure 5. 
  


Figure S3



Supplementary Tables 
Table S1: sgRNA used in generation of CRISPR-Cas9 modified mice 
Guide ID Target Sequence + PAM Mouse Generated Chr 
G3 Ly49g/a/h CATTCCCAAGATGAGTGAGCAGG ΔLy49-1 6 
I2 Ly49i GACCTCCGGCTCATTCATCGTGG C14B 6 
C1 Ly49c TCCCACGATGAGTGAGCCAGAGG C14B 6 
M1 Ly49m CGGGTGAGGCTTGAGGAGACAGG M1, M4, M7, M8 6 
G4 Ly49g GCAGAAACTAGTGAGGACTGAGG AG1, AG7 6 
A5 Ly49a GTGAGACCTGAGGAGACTAAAGG AG1, AG7, A15, A20 6 
T3 Ncr1 GGTACAGCATAGAGCTCACAAGG Ly49A-KI 7 
T1 Ncr1 GTGAGCTCTATGCTGTACCCTGG Ly49A-KI 7 
The names of the sgRNA guides (Guide ID) are provided along with the intended genomic targets, the 
sgRNA sequence including the “NGG” protospacer adjacent motif (PAM) site underlined, the mice 
generated with the sgRNA and the chromosomal location of the targeted gene. A complete list 
containing all relevant on-target and off-target sites in B6 mice is provided as supplemental file 
Table_S1.xls and references the specific guides using the Guide ID. In this file, individual on-target and 
potential off-target sites are indicated as identified by CCTop (see Methods). Specifically, the input 
sgRNA sequence along with the number of mismatches and the location of mismatches within the 12nt 
core (less likely to bind) or outside the core are shown. Chromosome positions of targets along with 
gene names, if available are indicated. Potential off-target sites within the target chromosome are 
highlighted and were carefully examined with sequence (Figure S1) and flow cytometric methods 
(Figure S2). Related to STAR Methods. 
Table S2: List of MCMV sgRNA target sites 
A complete list of all guides with no or minimal off-target sites is provided as supplemental file 
Table_S2.xls. In this file, individual on-target and potential off-target sites are indicated as identified by 
CCTop (see Methods). Specifically, the individual sgRNA sites only within the MCMV genome was 
interrogated for all CRISPR/Cas9 target sites. Any alternate cleavage sites are indicated. The two sgRNA 
guide sequences used in our experiments are identified as T303 (m06) and T18561 (m152) (see also 
Table S3) and is highlighted in yellow within the file. Related to STAR Methods.  
Table S3: sgRNAs specific for MCMV m06 or m152 
Guide 
ID 
Target sgRNA Sequence + PAM Forward Oligo (5' to 3') Reverse Oligo (5' to 3') 
T303 m06 AGAGTCTTACGTTAAGACAGAGG caccgAGAGTCTTACGTTAAGACAG aaacCTGTGTTAACGTAAGACTCTc 
T18561 m152 TATGGACGTGCGCATATTCGAGG caccgTATGGACGTGCGCATATTCG aaacCGAATATGCGCACGTCCATAc 
 
The names of the sgRNA guides (Guide ID) are provided (see also Table_S2.xls) along with the intended 
MCMV ORF targets, and the sgRNA sequence including the “NGG” protospacer adjacent motif (PAM) 
site underlined. Two oligos were used to generate duplex DNA used for cloning into the modified px330 
Cas9-encoding vector (see Methods). An additional guanine residue was appended to the forward oligo 
(and complementary cytosine to the reverse oligo) to enhance sgRNA production from the U6 promoter 
in cells. Related to STAR Methods.  
Table S4: The primers used for Ly49 gene sequence analysis 
Gene Fwd Primer Sequence  (5' to 3') Rev Primer Sequence (5' to 3') Amplicon 
size (nt) 
Klra1/Ly49a TCTTCCCTCCCATCTTTGTTCA TGGGTCAGTCCATGTCAGTG 439 
Klra2/Ly49b ATTGTTCTGCTCTGCGCATC AGAGTCAGGGTGTTTGGACC 409 
Klra3/Ly49c TCTTCCCTCCCGTCCTTGTA TGCATGTCAGGGTGTTTGGA 428 
Klra4/Ly49d TCACCCTCATGCATAACTAAGG CAGTCCATGCTGCAGTGTTT 421 
Klra5/Ly49e CTTCTCCGGGCCCTTGAATC GGCTGTATCAATGGTAGAATGGC 414 
Klra6/Ly49f CTCCCATACTTGTGCATAATCAAA GGATCAGTCCATGTCAGGGTG 427 
Klra7/Ly49g AACCAAGCCCCAATGAGATC GGTCAGTCCATGTCAGGGTG 411 
Klra8/Ly49h GGAACATTTTACTTTTCAATGAAAGCCT CTGTATCATCAGATCCAGGTACCTTT 324 
Klra9/Ly49i CAAGCCCCGATGAGATGGAT GGATCAGTCCATGTCAGGGTT 409 
Klra10/Ly49j CAAGCCCCGATGAGATGGAC GGATCAGTCCATGTCAGGGTA 409 
Klra13-ps/Ly49m CTTTTCTTCTCTCTCACCCTTATGCATAAC CCCAAGATGAGTGAGCAGGAGGT 278 
Klra14-ps/Ly49n ACTTCTTGTTTCCCAAGAAATGTTTTCTTACTG CACCCTTTCTCAACCTTCTGTATCACT 591 
Klra17/Ly49q GCCCATCTGGCTTCCTTTCT TGAGTCCCAGTCAGGGTCAT 533 
Gm15854/Ly49x TTCTCTCTTACCCTCGTGCATAAC GTGAGGTCAGTCCATGCTGAG 438 
Gm6584 AGCCAAGCCCAGATGAAATGA ACAGGGTTTCTCCCCTGAAA 428 
 
This table provides the primer sequences and amplicon lengths used for amplification and sequencing 
the Ly49 region of the murine NKC locus on chromosome 6. See Methods for sequencing conditions and 
Figure S1 for results. Related to STAR Methods.  
Table S5: The primers used for MCMV m06 and m152 gene sequence analysis 
ORF Fwd Sequence Primer (5' to 3') Rev Sequence Primer (5' to 3') Amplicon size (nt) 
m06 CACGCCCAAAATCACGCAAAC GGCGTAGTCGAATGGTACA 853 
m152 CGATGTCATCCTCGGATA GGCTACTCCCGAAAGAGTAA 578 
 
This table provides the primer sequences and amplicon lengths used for amplification and sequencing 
the viral ORFs m06 and m152 from MCMV. See Methods for sequencing conditions and Figure S5 for 
results. Related to STAR Methods. 
